The touchstone to evaluate accurately the aggressiveness and invasiveness of prostate cancer is something of a holy grail in the facet of urologic oncology. Gene expression and sequencing studies have improved our interpretations of the genetic determinants of the disease but are unsuccessful in the establishment of any unified classification to improve the molecular stratification. These questions addressing failure in rational drug design are difficult to answer in the multifaceted and heterogeneous pathogenesis of prostate cancer. In this review, we have developed a roadmap of the “recalcitrant prostate cancer proteome” to recognize the aspects of prostate cancer that may be helpful in effectively translating these findings to the clinic.
HuR., IsaacsW.B., LuoJ.A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities.Prostate2011 Mar 28, doi: 10.1002/pros.21382 [Epub ahead of print].
2.
SunS., SprengerC.C., VessellaR.L.Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.J Clin Invest2010; 120: 2715–30.
3.
JaglaM., FèveM., KesslerP.A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions.Endocrinology2007; 148: 4334–43.
4.
LiY., AlsagabiM., FanD., BovaG.S., TewfikA.H., DehmS.M.Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.Cancer Res2011; 71: 2108–17.
5.
WatsonP.A., ChenY.F., BalbasM.D.Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.Proc Natl Acad Sci U S A2010; 107: 16759–65.
6.
KobayashiM., HuangY., JinC.FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells.Prostate2011 Mar 28, doi: 10.1002/pros.21386 [Epub ahead of print].
7.
ReebC.A., GerlachC., HeinssmannM.A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode.Endocrinology2011 April 12 [Epub ahead of print].
8.
KawabataR., OieS., OkaT., TakahashiM., KanayamaH., ItohK.Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.Int J Oncol2011; 38: 665–76.
9.
KawabataR., OieS., TakahashiM., KanayamaH., OkaT., ItohK.Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.Int J Oncol2011; 38: 1489–500.
10.
NakajimaY., AkaogiK., SuzukiT.Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ER{beta} and KLF5.Sci Signal2011; 4: ra22.
11.
LeungY.K., HoS.M.Estrogen receptor {beta}: switching to a new partner and escaping from estrogen.Sci Signal2011; 4: pe19.
12.
HuW.Y., ShiG.B., LamH.M.Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells.Endocrinology2011 Mar 22 [Epub ahead of print].
13.
HirvonenJ., RajalinA.M., WohlfahrtG., AdlercreutzH., WähäläK., AarnisaloP.Transcriptional activity of estrogen-related receptor γ (ERRγ) is stimulated by the phytoestrogen equol.J Steroid Biochem Mol Biol2011; 123: 46–57.
14.
DwyerM.A., JosephJ.D., WadeH.E.WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration.Cancer Res2010; 70: 9298–308.
15.
JohnsonJ.J., SyedD.N., SuhY.Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention.Cancer Prev Res (Phila)2010; 3: 1112–23.
16.
QiaoY., WangL., CaiL.Q., TanC., Imperato-McGinleyJ., ZhuY.S.Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.J Urol.2011; 185: 305–14.
17.
TaylorS.E., PatelI.I., SinghP.B.Elevated oestrogen receptor splice variant ERαΔ5 expression in tumour-adjacent hormone-responsive tissue.Int J Environ Res Public Health2010; 7: 3871–89.
18.
LaveryD.N., VillarongaM.A., WalkerM.M., PatelA., BelandiaB., BevanC.L.Repression of androgen receptor activity by HEYL, a third member of the hairy/enhancer-of-split-related family of notch effectors.J Biol Chem2011 March 17 [Epub ahead of print].
19.
UzohC.C., HollyJ.M., BiernackaK.M.Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.Br J Cancer2011; 104: 1587–93.
20.
RoellD., RöslerT.W., DegenS., MatuschR., BaniahmadA.Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation.Chem Biol Drug Des2011 [Epub ahead of print].
21.
PitchakarnP., SuzukiS., OgawaK.Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf.Cancer Lett2011; 306: 142–50.
22.
WangX.L., KongF., ShenT., YoungC.Y., LouH.X., YuanH.Q.Sesquiterpenoids from myrrh inhibit androgen receptor expression and function in human prostate cancer cells.Acta Pharmacol Sin2011; 32: 338–44.
23.
HildenbrandZ.L., MoluguS.K., HerreraN., RamirezC., XiaoC., BernalR.A.Hsp90 can accommodate the simultaneous binding of the FKBP52 and HOP proteins.Oncotarget2011; 2: 43–58.
24.
LamoureuxF., ThomasC., YinM.J.A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.Clin Cancer Res2011; 17: 2301–13.
25.
LiuR., ZhouZ., HuangJ., ChenC.PMEPA1 promotes androgen receptor-negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21 Cip1 signaling pathway.J Pathol2011; 223: 683–94.
26.
BarboroP., RepaciE., FerrariN., RubagottiA., BoccardoF., BalbiC.Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.Prostate2011 Feb 14, doi: 10.1002/pros.21366 [Epub ahead of print].
27.
KawabataR., OieS., OkaT., TakahashiM., KanayamaH., ItohK.Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.Int J Oncol2011; 38: 665–76.
28.
KampaM., TheodoropoulouK., MavromatiF.Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer.J Pharmacol Exp Ther2011; 337: 24–32.
29.
ThomasC., ZoubeidiA., KurumaH.Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.Mol Cancer Ther2011; 10: 347–59.
30.
ScharerC.D., McCabeC.D., Ali-SeyedM., BergerM.F., BulykM.L., MorenoC.S.Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells.Cancer Res2009; 69: 709–17.
31.
BonciD., CoppolaV., MusumeciM.The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.Nat Med2008; 14: 1271–7.
32.
PorkkaK.P., OggE.L., SaramäkiO.R.The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers.Genes Chromosomes Cancer2011; 50: 499–509.
33.
ZhengC., YinghaoS., LiJ.MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2.Med Oncol2011 Apr 13 [Epub ahead of print].
34.
MostertB., SieuwertsA.M., MartensJ.W., SleijferS.Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients.Expert Rev Mol Diagn2011; 11: 259–75.
35.
TangX., TangX., GalJ., KyprianouN., ZhuH., TangG.Detection of microRNAs in prostate cancer cells by microRNA array.Methods Mol Biol2011; 732: 69–88.
36.
WachS., NolteE., SzczyrbaJ.MiRNA profiles of prostate carcinoma detected by multi-platform miRNA screening.Int J Cancer2011 Mar 11 [Epub ahead of print].
37.
HaoY., ZhaoY., ZhaoX.Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling.Cancer Invest2011; 29: 318–24.
38.
ChiyomaruT., TataranoS., KawakamiK.SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer.Prostate2011 Feb 25 [Epub ahead of print].
39.
HagmanZ., LarneO., EdsjöA.miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.Int J Cancer2010; 127: 2768–76.
40.
GordanpourA., StanimirovicA., NamR.K.miR-221 is down-regulated in TMPRSS2: ERG fusion-positive prostate cancer.Anticancer Res2011; 31: 403–10.
41.
ÖstlingP., LeivonenS.K., AakulaA.Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.Cancer Res2011; 71: 1956–67.
42.
KowarschA., PreusseM., MarrC., TheisF.J.miTALOS: Analyzing the tissue-specific regulation of signaling pathways by human and mouse microRNAs.RNA2011; 17: 809–19.
43.
AlbertiniM.C., OlivieriF., LazzariniR.Predicting microRNA modulation in human prostate cancer using a simple String IDentifier (SID1.0).J Biomed Inform2011 Feb 18 [Epub ahead of print].
44.
VisvaderJ.E., LindemanG.J.Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.Nat Rev Cancer2008; 8: 755–68.
45.
FarooqiA.A., MansoorQ., IsmailM., BhattiS.Therapeutic effect of epigallocatechin-3-gallate (EGCG) and silibinin on ATM dynamics in prostate cancer cell line LNCaP.World Journal of Oncology2010; 1: 242–6.
46.
FarooqiA.A., BhattiS., RanaA.Shattering the underpinnings of neoplastic architecture in LNCaP: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation.J Exp Ther Oncol2011 (in press).
